Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06703476 · ClinicalTrials.gov registry record · Phase 3
A Study of Surgical Techniques During Cystectomy
A Phase 3 study of Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 7
- Study locations
NCT06703476 is a Phase 3 study of Bladder Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 530 participants, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06703476, a Phase 3 study of Bladder Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections after surgery. This trial will evaluate whether the following surgical methods influence outcomes: A ureteral stent is a thin tube that is placed in the ureter to drain urine from the kidney. Ureteral stents are often used to promote urine drainage after radical cystectomy, but may come at risk of urinary tract infection. Alvimopan is a standard drug used to promote return of bowel function following surgery. Doctors do not know whether alvimopan is beneficial in current clinical practice. The surgeon will decide whether participants will receive a stent and/or alvimopan, but if they are unsure what the best approach is, a surgical technique has been assigned by chance to them.
Conditions Studied
Interventions
- PROCEDURE Stent placement
- DRUG Alvimopan
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (Consent Only) - Commack
- Memorial Sloan Kettering Westchester (Consent Only) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Consent Only) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Consent Only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent Only) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2028-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06703476
The ClinicalTrials.gov registry entry for NCT06703476 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stent placement is the first listed.
NCT06703476 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06703476 about?
NCT06703476 is a clinical study titled "A Study of Surgical Techniques During Cystectomy". The purpose of this study is to look at two standard surgical techniques used during a radical cystectomy and see whether they influence outcomes such as length of stay in the hospital and infections after surgery. This trial will evaluate whether the following surgical methods influence outcomes: ...
What is the current status of trial NCT06703476?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2024-11-21. Estimated completion is 2028-11.
What conditions does trial NCT06703476 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT06703476?
The interventions under investigation include: Stent placement (PROCEDURE), Alvimopan (DRUG).
Who is sponsoring clinical trial NCT06703476?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06703476 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.